97 related articles for article (PubMed ID: 16673277)
1. Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.
Ludwig H; Linkesch W; Gisslinger H; Fritz E; Sinzinger H; Radaszkiewicz T; Chott A; Flener R; Micksche M
Cancer Immunol Immunother; 1987; 25(3):266-73. PubMed ID: 3677127
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis.
Lucijanic M; Krecak I; Soric E; Sabljic A; Galusic D; Holik H; Perisa V; Moric Peric M; Zekanovic I; Budimir J; Kusec R
Life (Basel); 2024 Apr; 14(4):. PubMed ID: 38672793
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders.
Yildiz A; Güryildirim M; Pepeler MS; Yazol M; Oktar SÖ; Acar K
Clin Appl Thromb Hemost; 2018 Oct; 24(7):1102-1108. PubMed ID: 29683036
[TBL] [Abstract][Full Text] [Related]
4. Essential thrombocythaemia.
Barranco-Lampón G; Martínez-Castro R; Arana-Luna L; Álvarez-Vera JL; Rojas-Castillejos F; Peñaloza-Ramírez R; Carballo-Zarate AA; Olarte-Carrillo I; Minamy JI; López-Salazar J; Navarrete JJ; Espinosa-Partida A; Ventura-Enríquez Y; Ruiz-Contreras JI; Aguirre-Reyes OG; Anaya-Cuéllar I; Aguilar-Luévano J; Díaz-Ramírez HF; Herrera-Olivares W; Aguilar-Hidalgo JA; Alcívar-Cedeño LM; Hernández-Caballero Á; Galaz-Cordero LE; Peña-Celaya JA; Báez-Islas PE; Bates-Martín RA; Cano-León AML; Espitia-Ríos ME; Barbosa D; Morales-Adrián J; Pacheco MJ; Delgado-López N; Neme-Yunes Y; Moralws-Hernández AE; Mújica-Martínez A; Pérez-Lizardi AB; Pérez-Gómez KD; Barragán-Ibáñez G; Martínez A; Flores-Ordúñez K; Ramírez-Hoyos P; Ángeles Rosales-López ML; Acosta-Maldonado BL; Jiménez-Ochoa MA; Garzón-Velásquez KB; Hernández-Ruiz E; McNally-Guillén BM; Saucedo-Montes EE; Aguilar-Andrade C; Vivas-Arteaga CL; Guerra-Alarcón LV; Milán-Salvatierra AI; Campa-Monroy DI; Cota-Rangel X; Estrada-Domínguez P; García-Camacho AS; García-Castillo C; Banda-García LI; Rodríguez-Sánchez V; Meillón-García LA; Urbina-Escalante E; Martínez-Ramírez MA; Loera-Fragoso SJ; Martínez-Coronel J; Zapata-Canto N; Gómez-Cortés SC; Medina-Coral JE; Mójica-Balderas L; Pérez-Zúñiga JM; Pérez FJ; López-Arroyo JL; Zazueta-Pozos JF; Romero-Martínez E; Romero-Rodelo H; Tapia-Enríquez AL; Soriano-Mercedes EJ; Salazar-Ramírez Ó; Vilchis-González SP; Tepepa-Flores F; Alvarado-Ibarra M
Gac Med Mex; 2022; 158(Supl 1):17-25. PubMed ID: 37734042
[TBL] [Abstract][Full Text] [Related]
5. The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep.
Accurso V; Santoro M; Mancuso S; Napolitano M; Carlisi M; Mattana M; Russo C; Di Stefano A; Sirocchi D; Siragusa S
Clin Med Insights Blood Disord; 2020; 13():2634853520978210. PubMed ID: 33447121
[TBL] [Abstract][Full Text] [Related]
6. Successive development of ischemic stroke and hemorrhagic stroke in a patient with essential thrombocythemia: a case report.
Chen X; Cao L; Feng H; Huang X
J Int Med Res; 2021 Jan; 49(1):300060520987718. PubMed ID: 33472495
[TBL] [Abstract][Full Text] [Related]
7. Ph
Košťál M; Schwarz J; Ovesná P; Penka M; Dulíček P;
J Thromb Thrombolysis; 2021 Jan; 51(1):112-119. PubMed ID: 32578055
[TBL] [Abstract][Full Text] [Related]
8. Essential thrombocythemia.
Brière JB
Orphanet J Rare Dis; 2007 Jan; 2():3. PubMed ID: 17210076
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders.
Thiele J; Kvasnicka HM
Semin Thromb Hemost; 2006 Apr; 32(3):219-30. PubMed ID: 16673276
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
Murphy S
Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
[TBL] [Abstract][Full Text] [Related]
11. Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia.
Schwarz J; Pytlík R; Doubek M; Brychtová Y; Dulícek P; Campr V; Kren L; Penka M
Semin Thromb Hemost; 2006 Apr; 32(3):231-45. PubMed ID: 16673277
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
13. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
Thiele J; Kvasnicka HM
Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
